AU-935 (HB-EGF)
Non-surgical repair of tympanic membrane perforations
Pre-clinicalActive
Key Facts
Indication
Non-surgical repair of tympanic membrane perforations
Phase
Pre-clinical
Status
Active
Company
About Auration Biotech
Auration Biotech is an emerging player in the otology therapeutics space, advancing a pipeline of non-surgical treatments for common ENT disorders. Its lead programs, AU-935 and AU-934, aim to address significant unmet needs in tympanic membrane repair and alternatives to ear tube surgery, respectively. As a private, preclinical company, it operates with a lean structure and is likely reliant on venture funding or partnerships to advance its programs toward clinical trials. The company's success hinges on translating its targeted biologics approach into effective, convenient treatments that can shift standard care paradigms.
View full company profile